



Universiteit  
Leiden  
The Netherlands

## Optimizing antiseizure medication treatment in glioma patients with epilepsy

Meer, P.B. van der

### Citation

Meer, P. B. van der. (2023, November 2). *Optimizing antiseizure medication treatment in glioma patients with epilepsy*. Retrieved from <https://hdl.handle.net/1887/3655923>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3655923>

**Note:** To cite this publication please use the final published version (if applicable).



## PART II

Antiseizure medication tolerability



## **CHAPTER 8**

### **Effect of Antiepileptic Drugs in Glioma Patients on Self-Reported Depression, Anxiety, and Cognitive Complaints**

Journal of Neuro-Oncology. 2021;153(1):89-98.

Pim B. van der Meer  
Johan A.F. Koekkoek  
Martin J. van den Bent  
Linda Dirven  
Martin J.B. Taphoorn

## Abstract

### Introduction

AEDs have been associated with depression, anxiety, and cognitive impairment, all frequent complications of glioma and its subsequent treatment, with considerable morbidity and an adverse effect on health-related quality of life. This study aimed to determine the independent association between AED use and self-reported depression, anxiety, and subjective cognitive impairment in glioma patients.

### Methods

In this multicenter cross-sectional study, depression and anxiety were assessed with the HADS and subjective cognitive impairment was assessed with the MOS-CFS. Univariable logistic regression analyses were performed on all potential confounding predictor variables. Potential confounders were included in the multivariable analyses if  $p$ -value $<0.1$ , to evaluate whether use of AEDs was independently related to depression, anxiety, and/or subjective cognitive impairment.

### Results

A total of 272 patients were included. Prevalence of depression differed significantly between patients not using (10%) and using AEDs (21%, unadjusted Odds Ratio [uOR]=2.29 [95%CI=1.05-4.97],  $p=0.037$ ), but after correction for confounders the statistical significant difference was no longer apparent (adjusted Odds Ratio [aOR]=1.94 [95%CI=0.83-4.50],  $p=0.125$ ). Prevalences of anxiety (aOR=1.17 [95%CI=0.59-2.29],  $p=0.659$ ) and subjective cognitive impairment (aOR=0.83 [95%CI=0.34-2.04],  $p=0.684$ ) did not differ significantly before or after adjustment of confounders between patients not using (19% and 16%, respectively) and using AEDs (26% and 21%, respectively).

### Conclusions

Our results indicate AED use was not independently associated with concurrent depression, anxiety, or subjective cognitive impairment in glioma patients. Alternative factors seem to have a greater contribution to the risk of developing neuropsychiatric symptoms in glioma patients.

---

### Keywords

Anticonvulsants, seizures, glioma, depression, anxiety, cognition

## Introduction

Gliomas account for almost 80% of all primary malignant brain tumours.<sup>1</sup> Patients with a glioma may face a variety of symptoms including mood disorders, cognitive dysfunction, and seizures.<sup>2-5</sup> Between 30-85% of patients with grade II-IV glioma experience epileptic seizures during the course of their disease.<sup>6, 7</sup> Subjective cognitive impairment (80%, assessed by reviewing medical records retrospectively) as well as moderate levels of self-reported anxiety (30-35%, assessed with the Hospital Anxiety and Depression Scale [HADS]) or depression (13-17%, assessed with the HADS) are common neurologic and psychiatric symptoms in glioma patients.<sup>8, 9</sup> Multiple studies have tried to identify associations between subjective cognitive impairment, anxiety, or depression and patient-, tumour-, and treatment-related factors in glioma patients. A consistent association across studies has been found between depression on one side and poor physical functioning, reduced health-related quality of life, and decreased survival on the other.<sup>5</sup> However, the association between subjective cognitive impairment, anxiety, or depression and risk factors such as sex, educational level, a previous psychiatric history, and antiepileptic drugs (AEDs) in glioma patients is less clear, with existing evidence being conflicting.<sup>5, 10-14</sup>

To prevent seizure recurrence, AEDs are generally indicated in all patients with a first seizure due to a brain tumour.<sup>7, 15</sup> Most AEDs are thought to have mood-modulating effects and some AEDs have been associated with the onset of depression and anxiety in epilepsy patients.<sup>16</sup> One of the most commonly prescribed AEDs in the glioma population, levetiracetam (LEV),<sup>17-19</sup> has been associated with the greatest risk of psychiatric and behavioural adverse effects compared to other AEDs.<sup>20</sup> Recently, three studies in the glioma population showed that LEV was associated with a higher risk of self-reported and clinician-diagnosed psychiatric adverse events, including anxiety.<sup>11, 21, 22</sup> Another commonly prescribed AED in the glioma population, valproic acid (VPA),<sup>23</sup> has been associated with decreased psychiatric and behavioural adverse effects in non-brain tumour-related epilepsy (BTRE) patients.<sup>24</sup> In addition, AEDs have been associated with objective as well as subjective cognitive impairment, in both epilepsy<sup>25</sup> and glioma patients.<sup>12, 26</sup> Especially the first generation of AEDs, which includes VPA, have been related to cognitive impairment in glioma patients.<sup>12, 26</sup> LEV, on the other hand, does not seem to have any negative effects on neurocognitive functioning of (non-)BTRE patients.<sup>27, 28</sup> Adverse drug effects are considerably more often reported in glioma patients compared to patients with non-BTRE.<sup>15, 19, 29</sup> We expect glioma patients are at higher risk of developing depression, anxiety, or cognitive adverse effects from AEDs than non-BTRE patients.

Given neuropsychiatric symptoms are frequent complications of the tumour itself and its subsequent treatment, with considerable morbidity and an adverse effect on health-related quality of life,<sup>30, 31</sup> aim of this study was to determine whether AED use independently contributed to depression, anxiety, and subjective cognitive impairment in glioma patients.

Based on previous literature, we hypothesized that: (I) use of AEDs was independently associated with self-reported depression, anxiety, and subjective cognitive impairment in glioma patients; (II) glioma patients using LEV monotherapy are more depressed and/or anxious than patients on VPA monotherapy; and (III) glioma patients using VPA monotherapy report more often subjective cognitive impairment than patients on LEV monotherapy.

## Methods

### Participants

This observational study included adult patients ( $\geq 18$  years) with a histologically confirmed supratentorial grade II-IV glioma, according to the 2016 World Health Organization (WHO) classification of tumours of the central nervous system,<sup>32</sup> who visited the neuro-oncology outpatient clinic in one of three large referral centers in the Netherlands between June 1<sup>st</sup>, 2017 and June 1<sup>st</sup>, 2018: Leiden University Medical Center in Leiden, Haaglanden Medical Center in the Hague, and the Erasmus Medical Center in Rotterdam. Patients were not eligible if they had insufficient understanding of the Dutch language in order to read the information letter and complete the self-reported questionnaires. The medical ethics committees of the participating institutions approved the study protocol and all patients provided written informed consent before participation.

### Clinical data and used instruments

Clinical data retrieved from the medical records included patient-related and tumour-related characteristics, current and previous antitumour treatment, Karnofsky Performance Status (KPS), current AED use, other prescription medications, and AED load. AED load is defined as the ratio between the prescribed daily dosage and the defined daily dosage (DDD) as defined by the WHO (Supplementary Table 1). For instance, a patient is prescribed 1500 milligram VPA and 300 mg lacosamide (LCM) each day. The DDD of VPA is 1500 mg and of LCM 300 mg. His/her AED load is 2 ( $[1500/1500] + [300/300]$ ).<sup>33</sup> Use of prescription medications, excluding AEDs, with  $>1\%$  risk of developing depression, anxiety, or cognitive adverse effects, were extracted from the medical records. The risk of potential adverse drug reactions and treatment indications of medications was based on the Dutch 'Farmacotherapeutisch Kompas' (Supplementary Table 2).<sup>34</sup> Patients were classified as using either none or at least one drug, separately for each of the three adverse effects. Mood stabilizing and anxiolytic medication could either be AEDs (e.g. VPA) or other prescription medications (e.g. citalopram), which were included separately as potential confounders. Medication taken as needed was excluded.



A study-specific questionnaire was used to assess other potential confounders (i.e. level of education, marital status, ethnicity, employment status, social support, history of mood disorder treatment, and mood disorder[s] in the family). Seizure severity, a potential confounding variable, was assessed with a modified version of the Liverpool Seizure Severity Scale (LSSS).<sup>35</sup> Depression and anxiety symptoms were assessed with the HADS questionnaire. A cut-off of  $\geq 8$  points on the depression or anxiety domain was used to classify patients as depressed or anxious.<sup>36</sup> Subjective cognitive impairment was assessed with the Medical Outcomes Study-Cognitive Functioning Scale (MOS-CFS).<sup>37</sup> A cut-off of  $\geq 2$  standard deviations (SD) below the mean of the reference population was used to classify patients as subjectively cognitively impaired.<sup>12,38</sup> More extensive details on the questionnaires can be found in Supplementary Table 3.

### Statistical analyses

All statistical analyses were performed with SPSS 23.0 for Windows, and a  $p$ -value ( $p$ ) $<0.05$  was considered significant. A non-response analysis concerning the most important patient characteristics was performed using the  $\chi^2$ -test for proportions and the Student's  $t$ -tests or Mann-Whitney U-test for continuous variables (depending on the distribution of the data) to assess the extent of response bias. In addition, the point prevalence rates of depression, anxiety, and subjective cognitive impairment of glioma patients was compared with normative data using the Student's  $t$ -tests for comparison of means.<sup>37, 39</sup>

The DAG (Directed Acyclic Graph) representation was used to identify potential confounders based on prior knowledge from the literature, meaning a confounder must be associated with both the determinant (i.e. AED use) and the outcome, but not lay in the causal path.<sup>40</sup> In order to assess which tumour-related, treatment-related and patient-related characteristics were associated with depression, anxiety, and subjective cognitive impairment, univariable logistic regression analyses (per outcome) with all potential confounders were performed (Supplementary Tables 4, 5, and 6). Probability for entry in the multivariable logistic regression was set at  $p<0.10$  in univariable analysis. Based on previously conducted simulation studies, a maximum of 9, 13, and 10 parameters were included in the multivariable regression model for depression, anxiety, and subjective cognitive impairment, respectively.<sup>41</sup> Correlation analyses were performed to identify multicollinearity, with a cut-off set at a variance inflation factor of  $>5$ .

Three multivariable logistic regression analyses were performed to identify whether use of AEDs (none versus at least one) was independently related to depression, anxiety, or subjective cognitive impairment. Previously mentioned potential confounding variables, with  $p<0.10$  in univariable logistic regression, were included. Subsequently, three additional multivariable logistic regression analyses were performed, now with a more specific definition of AED use ([1] no AED use; [2] LEV monotherapy; [3] VPA monotherapy; [4] other AED use) in order to assess if the association between AEDs and depression, anxiety,

and subjective cognitive impairment differed between types of AEDs, at the expense of a loss of power. The same potential confounders as in the previous analyses were included. Two sensitivity analyses were performed with less stringent cut-offs for subjective cognitive impairment (1 SD and 1.5 SD). No sensitivity analyses were performed with the more stringent alternative cut-off ( $\geq 11$  points) on the depression and anxiety domain, as this would result in an insufficient number of depressive and anxious patients to allow inclusion of confounding parameters.

## Results

Table 1 shows the sociodemographic and clinical characteristics of the included patients. A total of 536 eligible glioma patients were approached for participation, of which 272 (51%) completed the questionnaires. Most included patients were male (58%), diagnosed with glioblastoma (32%), had a partner (80%), a high level of education (43%), received radiotherapy (80%), and chemotherapy (71%). A total of 88/272 of the included patients did not use AEDs, 85 patients used LEV monotherapy, 32 patients used VPA monotherapy, 15 patients used monotherapy of other AEDs, and 52 patients used polytherapy AEDs. All 272 patients completed the questionnaires on depression, anxiety, and subjective cognition. The non-response analysis showed that patients who participated had less often KPS scores  $< 70$  (2% versus 9%,  $p=0.001$ ) and a higher mean age (54 [SD=13] versus 50 [SD=12] years,  $p=0.001$ ) compared to patients who did not participate in the study, while they did not differ significantly on other patient- and disease-related characteristics.

### Depression

Glioma patients had a significantly higher mean depression score when compared with Dutch normative data (4.1 [SD=3.9] versus 3.4 [SD=3.3], respectively,  $p=0.006$ ), but this difference was not considered clinically relevant.<sup>39</sup> A total of 47/272 (17%) patients were considered depressed. Prevalence of depression differed significantly between patients not using (10%) and using AEDs (21%, unadjusted Odds Ratio [uOR]=2.29 [95%CI=1.05-4.97],  $p=0.037$ ), but this significant difference disappeared after adjustment for potential confounders (adjusted Odds Ratio [aOR]=1.94 [95%CI=0.83-4.50],  $p=0.125$ ). Use of prescription medications with  $> 1\%$  risk of depressive adverse effects (excluding AEDs) was still independently associated with a higher prevalence of depression after adjustment for confounders, which was true as well for being incapacitated to work and KPS score  $< 70$  (Table 2).

We hypothesized that patients using LEV monotherapy were more depressed than patients using VPA monotherapy. However, the prevalence of depression was not significantly higher for LEV monotherapy (22%) compared to VPA monotherapy (19%),

**Table 1.** Sociodemographic and clinical characteristics of the n=272 study population.

	Number of patients
Mean age in years (SD)	54 (12)
Sex, n (%)	
Female	113 (42%)
Male	159 (58%)
Median time since diagnosis in months (IQR)	77 (18-113)
Histological diagnosis last resection, n (%)	
Low-grade	135 (50%)
Diffuse astrocytoma NOS	16 (6%)
Diffuse astrocytoma IDH-mutant	36 (13%)
Oligodendroglioma NOS	7 (3%)
Oligodendroglioma IDH-mutant 1p/19q codeletion	66 (24%)
Oligoastrocytoma NOS	6 (2%)
Pleiomorphic xanthroastrocytoma	4 (1%)
High-grade	137 (50%)
Diffuse astrocytoma IDH-wildtype	5 (2%)
Anaplastic astrocytoma NOS	11 (4%)
Anaplastic astrocytoma IDH-wildtype	2 (1%)
Anaplastic astrocytoma IDH-mutant	11 (4%)
Anaplastic oligodendroglioma NOS	2 (1%)
Anaplastic oligodendroglioma IDH-mutant 1p/19q codeletion	18 (7%)
Glioblastoma NOS	41 (15%)
Glioblastoma IDH-wildtype	38 (14%)
Glioblastoma IDH-mutant	9 (3%)
Extent of last resection, n (%)	
Biopsy	37 (14%)
Resection	227 (83%)
Missing	8 (3%)
Previously received radiotherapy, n (%)	
Yes	217 (80%)
No	55 (20%)
Previously received chemo- and/ or immunotherapy <sup>1</sup> , n (%)	
Temozolomide	148 (54%)
PCV	47 (21%)
Lomustine	10 (4%)
Temozolomide rechallenge	22 (8%)
Immunotherapy	8 (3%)
Other	2 (1%)
No chemo- and/or immunotherapy	79 (29%)
Tumour lobe, n (%)	
Frontal	162 (60%)
Non-frontal	110 (40%)

**Table 1.** Continued

	Number of patients
Epilepsy type, n (%)	
Focal	74 (27%)
Focal to bilateral tonic-clonic	48 (18%)
Focal & focal to bilateral tonic-clonic	84 (31%)
Unknown	7 (3%)
No epilepsy	59 (22%)
KPS, n (%)	
≥70	266 (98%)
<70	6 (2%)
Level of education, n (%)	
Low	72 (26%)
Medium	82 (30%)
High	118 (43%)
Ethnicity, n (%)	
Caucasian	252 (93%)
Other	12 (4%)
Missing	8 (3%)
Marital status, n (%)	
Partner	222 (82%)
No partner	50 (18%)
Current employment status, n (%)	
Not incapacitated to work	199 (73%)
Incapacitated to work	73 (27%)
Social support <sup>2</sup> , n (%)	
Adequate	263 (97%)
Not adequate	9 (3%)
History of mood disorder treatment (prior to glioma diagnosis) , n (%)	
Yes <sup>3</sup>	31 (11%)
No	241 (89%)
Mood disorder treatment (started after glioma diagnosis) , n (%)	
Yes <sup>3</sup>	33 (12%)
No	239 (88%)
Mood disorder in family <sup>4</sup> , n (%)	
Yes	79 (29%)
No	193 (71%)

<sup>1</sup>Percentages do not add-up to 100%, since patients could have received more than one type of chemo- and/or immunotherapy; <sup>2</sup>Social support was measured with two questions (yes/no) concerning if patient had friends or family that can help when you need them and you can speak to confidentially (not adequate social support = ≥1 no); <sup>3</sup>Psychologically and/ or medically; <sup>4</sup>First and/ or second degree relatives with diagnosis of depression, anxiety or bipolar disorder; IDH=Isocitrate dehydrogenase; IQR=Interquartile range; KPS=Karnofsky Performance Status; NOS=Not otherwise specified; SD=Standard deviation

neither before or after adjustment for potential confounders (aOR=0.76 [95%CI=0.26-2.23,  $p=0.616$ ). No significant differences were found comparing LEV monotherapy with patients not using AEDs (10%) or other AEDs (19%), neither before or after correction for potential confounders [Supplementary Table 7]).

### Anxiety

The mean anxiety score of glioma patients was not significantly different from Dutch normative data (5.0 [SD=3.7] versus 5.1 [SD=3.6],  $p=0.535$ ).<sup>39</sup> A total of 64 (24%) of all 272 included glioma patients were considered anxious. Prevalence of anxiety did not differ significantly between patients not using (19%) and using AEDs (26%, uOR=1.43 [95%CI=0.77-2.68],  $p=0.259$ ) and adjustment for confounders did not alter the results (aOR=1.17 [95%CI=0.59-2.29],  $p=0.659$  [Table 3]). Only history of mood disorder treatment was independently associated with anxiety after correction of confounders.

**Table 2.** Unadjusted and adjusted odds ratios of the predictor variables of depression in the multivariable analysis.

Parameter <sup>1</sup>	Depression ( $\geq 8$ points on the HADS-D)						
	uOR	95% CI	p-value	aOR	95% CI	p-value	
Current AED use, dichotomised	No AEDs (ref.)						
	$\geq 1$	2.29	1.05-4.97	0.037*	1.94	0.83-4.50	0.125
Medications > 1% risk of DAEs <sup>2</sup>	None (ref.)						
	$\geq 1$	2.18	1.14-4.19	0.019*	2.27	1.12-4.62	0.024*
Seizure severity		1.03	1.00-1.07	0.055	1.02	0.99-1.06	0.251
Level of education	Low (ref.)						
	Medium/ high	2.84	1.15-7.00	0.024*	2.18	0.85-5.59	0.105
Employment status	Not incapacitated to work (ref.)						
	Incapacitated to work	2.15	1.11-4.15	0.023*	2.01	0.99-4.06	0.052
Most recent tumour grade <sup>3</sup>	Low (grade II, ref.)						
	High (grade III & IV)	0.50	0.26-0.95	0.034*	0.50	0.25-1.03	0.059
KPS	$\geq 70$ (ref.)						
	<70	10.37	1.84-58.42	0.008*	9.34	1.53-56.90	0.015*

<sup>1</sup>Univariable analyses on all predictor variables of depression in this study can be found in the supplementary table 4; <sup>2</sup>Excluding AEDs; <sup>3</sup>Diffuse astrocytoma isocitrate dehydrogenase (IDH)-wildtype was considered high-grade; \* $p<0.05$ ; AED=Antiepileptic Drug; aOR=adjusted Odds Ratio; CI=Confidence Interval; DAEs=Depressive Adverse Effects; HADS-D=Hospital Anxiety and Depression Scale-Depression subscale; KPS=Karnofsky Performance Status; ref.=reference category; uOR=unadjusted Odds Ratio

**Table 3.** Unadjusted and adjusted odds ratios of the predictor variables of anxiety in the multivariable analysis.

Parameter <sup>1</sup>		Anxiety ( $\geq 8$ points on the HADS-A)					
		uOR	95% CI	p-value	aOR	95% CI	p-value
Current AED use, dichotomised	No AEDs (ref.)						
	$\geq 1$	1.43	0.77-2.68	0.259	1.17	0.59-2.29	0.659
Seizure severity		1.03	1.00-1.07	0.044*	1.03	1.00-1.06	0.091
Age		0.98	0.96-1.00	0.075	0.98	0.96-1.01	0.194
Ethnicity	Caucasian (ref.)						
	Other	3.50	1.09-11.28	0.036*	3.17	0.94-10.75	0.064
Social support	Adequate (ref.)						
	Not adequate	4.32	1.13-16.61	0.033*	3.73	0.86-16.26	0.080
History of mood disorder treatment <sup>2</sup>	No (ref.)						
	Yes	3.15	1.45-6.81	0.004*	2.76	1.23-6.19	0.014*

<sup>1</sup>Univariable analyses on all predictor variables of anxiety in this study can be found in the supplementary table 5; <sup>2</sup>Prior to glioma diagnosis; \* $p < 0.05$ ; AED=Antiepileptic Drug; aOR=adjusted Odds Ratio; CI=Confidence Interval; HADS-A=Hospital Anxiety and Depression Scale-Anxiety subscale; ref.=reference category; uOR=unadjusted Odds Ratio

We hypothesized that patients using LEV monotherapy were more anxious than patients using VPA monotherapy. When comparing LEV with other AEDs or patients not using AEDs, prevalence of anxiety was not significantly higher for LEV monotherapy (32%), VPA monotherapy (16%, aOR=0.55 [95%CI=0.19-1.65],  $p=0.289$ ), other AEDs (22%), or patients not using AEDs (19%), neither before nor after adjustment of potential confounders (Supplementary Table 8).

### Subjective cognitive functioning

The mean subjective cognitive functioning score of glioma patients was significantly lower than normative data (66.9 [SD=21.3] versus 81.9 [SD=16.9],  $t(271)=-11.64$ ,  $p < 0.001$ )<sup>37</sup>. A total of 19% (52/272) of patients were considered subjectively cognitively impaired. Prevalence of subjective cognitive impairment did not differ between patients not using (16%) and using AEDs (21%, uOR=1.38 [95%CI=0.70-2.70],  $p=0.353$ ) and adjustment of confounders did not alter the results (aOR=0.83 [95%CI=0.34-2.04],  $p=0.684$  [Table 4]). Solely seizure severity was independently associated with subjective cognitive impairment after correction of confounders. Alternate cut-offs for subjective cognitive dysfunction did not result in different results (data not shown).

We hypothesized that patients using VPA monotherapy reported more often subjective cognitive impairments than patients using LEV monotherapy. The prevalence of subjective cognitive impairment was not significantly higher for VPA monotherapy (28%) compared to LEV monotherapy (14%, aOR=0.40 [95%CI=0.14-1.11],  $p=0.078$ ), other AEDs (25%),

**Table 4.** Unadjusted and adjusted odds ratios of the predictor variables of subjective cognitive impairment in the multivariable analysis.

Parameter <sup>1</sup>		Impaired subjective cognition ( $\geq 2SD$ below the mean of normative data from the MOS)					
		uOR	95% CI	p-value	aOR	95% CI	p-value
Current AED use, dichotomised	No AEDs (ref.)						
	$\geq 1$	1.38	0.70-2.70	0.353	0.83	0.34-2.04	0.684
Medications >1% risk of CAEs <sup>2</sup>	None (ref.)						
	$\geq 1$	2.34	1.09-5.04	0.030*	2.18	0.97-4.88	0.059
Seizure severity		1.04	1.01-1.08	0.012*	1.04	1.00-1.07	0.044*
Total AED load		1.36	0.98-1.91	0.070	1.31	0.84-2.05	0.236
Sex	Female (ref.)						
	Male	0.59	0.32-1.09	0.093	0.61	0.32-1.15	0.125
Social support	Adequate (ref.)						
	Not adequate	3.58	0.93-13.84	0.064	2.38	0.53-10.80	0.260
Mood disorder in family <sup>3</sup>	No (ref.)						
	Yes	1.89	1.01-3.55	0.047*	1.53	0.77-3.00	0.223

<sup>1</sup>Univariable analyses on all predictor variables of subjective cognitive impairment in this study can be found in the supplementary table 6; <sup>2</sup>Excluding AEDs; <sup>3</sup>First and/ or second degree relatives; \* $p < 0.05$ ; AED=Antiepileptic Drug; aOR=adjusted Odds Ratio; CAEs=Cognitive Adverse Effects; CI=Confidence Interval; MOS=Medical Outcomes Study; ref.=reference category; uOR=unadjusted Odds Ratio

or patients not using AEDs (16%), neither before nor after adjustment for potential confounders (Supplementary Table 9). Alternate cut-offs did not give different results (data not shown).

## Discussion

Previous studies have shown that depression (13-17%), anxiety (30-35%), and subjective cognitive impairment (80%) frequently occur in glioma patients.<sup>8,9</sup> Numerous factors can be the causative or contributing factor of these impactful symptoms in glioma patients,<sup>30,31,42</sup> including AEDs.<sup>12,16,20,25,26</sup> The above mentioned neuropsychiatric symptoms are commonly reported as adverse effects of AEDs and glioma patients seem to be more vulnerable for adverse drug reactions of AEDs compared to patients with non-BTRE.<sup>15,19,29</sup> Therefore, we hypothesized that AED use is independently associated with self-reported depression, anxiety, and subjective cognitive impairment in glioma patients. In addition, we hypothesized patients on LEV would have an increased risk for depression and anxiety, while patients on VPA would have an increased risk for subjective cognitive impairment.

The findings in this study, however, do not support any of the three hypotheses. Although we found that the prevalence of depression was significantly higher in patients using AEDs compared to patients not using AEDs, this effect disappeared after adjustment for potential confounders, suggesting that the risk of depression is caused by other factors than AED use. Thereby, a lack of sufficient statistical power might have played a role in the absence of a statistically significant difference between AED types.

LEV has generally become one of the preferred AEDs in glioma patients due to the lack of any known pharmacological interactions.<sup>15</sup> A perceived higher risk of psychiatric adverse effects in patients on LEV is a concern of physicians and sometimes a reason to choose another AED over LEV.<sup>11,43</sup> Similar considerations apply to VPA with regard to a perceived higher risk of cognitive adverse effects.<sup>12</sup> Our data showed that the risk of having depression, anxiety, or subjective cognitive impairment does not significantly differ between patients on LEV, VPA, other AEDs and patients not using AEDs. Therefore, choosing certain AEDs over others or withholding AEDs in order to reduce the risk of depression, anxiety, or subjective cognitive impairment does in general not seem to be justified by our results. Nevertheless, on an individual basis different choices can be made.

Our results are in contrast with other studies in brain tumour patients, demonstrating that LEV had an increased risk for psychiatric adverse effects, including anxiety.<sup>11,21,22</sup> This might be partly due to differences in patient populations,<sup>22</sup> the instrument used for measurement of anxiety,<sup>11,21</sup> and/ or adjustment of different confounding variables.<sup>11,21,22</sup> Nonetheless it remains unclear why certain confounding variables in other studies, such as a tumour in the frontal lobe,<sup>11,21,22</sup> were not related to depression and/or anxiety in our study. We found that both prescription medications (excluding AEDs) with >1% risk of depression as adverse effect and poor performance status were the most important contributing factors for developing depression. In case of anxiety, a history of mood disorder treatment was the most contributing factor, and in case of subjective cognitive impairment it was seizure severity. Particularly the use of prescription medications other than AEDs with a risk of developing depression is of interest, as this could easily be adapted by a physician. Replacing medication with a relevant risk of depression as adverse effect by medication with a lower risk, should be considered at a low threshold in glioma patients with depressive mood symptoms. For instance, a dopamine-antagonist such as metoclopramide, which has a >1% risk of depression as adverse effect, can be exchanged for a 5HT<sub>3</sub>-antagonist like ondansetron as anti-emetic prophylaxis for chemotherapy induced nausea and vomiting. The limited use of older AEDs, such as phenytoin and phenobarbital, which are known for their cognitive adverse effects,<sup>26</sup> might explain the absence of an association in our study between AED use and subjective cognitive impairment, which is in contrast to what has been reported previously.<sup>12</sup> Of note, LEV has even been associated with an improved verbal memory in glioma patients,<sup>28</sup> although cognitive functioning was measured objectively instead of subjectively as in our study.



Typically, the correlation between subjective and objective measures of cognition is regarded low, with subjective cognitive symptoms being more closely related to emotional and mental symptoms.<sup>10</sup>

Nevertheless, our findings need to be interpreted carefully. In at least 13 patients treatment with LEV, VPA, and/ or topiramate was discontinued or adjusted due to psychiatric adverse effects related to the AED, according to the treating physician. Moreover, only 32 patients used VPA monotherapy and a lack of statistical power might have played a role in the absence of an association between VPA and subjective cognitive impairment. The prevalence of subjective cognitive impairment was twice as high in patients using VPA monotherapy (28%) compared to LEV monotherapy (14%) or no AEDs (16%). Due to the cross-sectional nature of our observational study we cannot establish or refute a definitive causal link between AED use and concurrent depression, anxiety, or subjective cognitive impairment in glioma patients. Despite including a wide variety of potential confounders in this study, residual confounding might still be present as some potential confounders were not incorporated in the analysis included (e.g. pre-existing conditions with a comorbidity index). An ongoing randomized controlled clinical trial also assessing depression, anxiety, and subjective cognitive impairment in patients on LEV versus VPA may contribute to elucidate this issue (ClinicalTrials.gov Identifier: NCT03048084).

A strength of our study is that we included all types of diffuse glioma patients and did not exclude certain patients, such as patients with a (family) history of psychiatric disorder,<sup>11</sup> but instead included this as a potential confounder. In addition, we included prescription medications other than AEDs with >1% risk of depression as a relevant confounder, which has not been reported before, and found an association with a higher risk of depression. Although the non-response analysis showed that the percentage of patients in the study population with poor performance status was significantly lower and the mean age higher, the actual differences were not clinically relevant. Therefore, our results can be considered generalizable to the general glioma population.

## Conclusion

Our results suggest that AED use was not associated with a higher risk of developing depression, anxiety, or subjective cognitive impairment in glioma patients, as there were no significant differences between patients using and not using AEDs, or between different types of AEDs. The risk of having depression, anxiety, or subjective cognitive impairment in glioma patients seems mainly be related to alternative factors. Based on these findings, choosing certain AEDs over others solely in order to reduce the risk of depression, anxiety, or subjective cognitive impairment does not seem to be justified. However, results from larger, preferably prospective, studies are needed to confirm our findings.

---

### **Funding**

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

### **Conflict of interest statement**

All authors declare no competing interests.

### **Availability of data and material**

Data are available upon reasonable request.

### **Code availability**

Not applicable.

### **Author's contribution**

PBvdM, JAFK, MJvdB, LD, and MJBT designed the study. Data collection was performed by PBvdM. PBvdM performed data-analysis with input from LD. PBvdM wrote the first and successive versions of the manuscript. All authors contributed to the interpretation of the results, intellectual content, critical revisions to the drafts of the paper, and approved the final version. PBvdM had full access to all the data in the study and had final responsibility for the decision to submit for publication.

### **Ethics committee approval**

This cross-sectional study was approved by the medical ethical committees of all participating centers.

### **Consent to participate**

All participants provided informed consent before study procedures.

### **Consent for publication**

Not applicable.

## References

1. Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. Epidemiology and molecular pathology of glioma. *Nature clinical practice Neurology*. 2006;2(9):494-503; quiz 1 p following 16.
2. Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. *Neuro-oncology*. 2012;14:17-24.
3. Fox SW, Lyon D, Farace E. Symptom clusters in patients with high-grade glioma. *J Nurs Scholarsh*. 2007;39(1):61-7.
4. Lemke DM. Epidemiology, diagnosis, and treatment of patients with metastatic cancer and high-grade gliomas of the central nervous system. *J Infus Nurs*. 2004;27(4):263-9.
5. Rooney AG, Carson A, Grant R. Depression in cerebral glioma patients: a systematic review of observational studies. *Journal of the National Cancer Institute*. 2011;103(1):61-76.
6. Lote K, Stenwig AE, Skullerud K, Hirschberg H. Prevalence and prognostic significance of epilepsy in patients with gliomas. *European journal of cancer*. 1998;34(1):98-102.
7. van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. *The Lancet Neurology*. 2007;6(5):421-30.
8. Ford E, Catt S, Chalmers A, Fallowfield L. Systematic review of supportive care needs in patients with primary malignant brain tumors. *Neuro-oncology*. 2012;14(4):392-404.
9. Mukand JA, Blackinton DD, Crincoli MG, Lee JJ, Santos BB. Incidence of Neurologic Deficits and Rehabilitation of Patients with Brain Tumors. *American Journal of Physical Medicine & Rehabilitation*. 2001;80(5):346-50.
10. Gehring K, Taphoorn MJB, Sitskoorn MM, Aaronson NK. Predictors of subjective versus objective cognitive functioning in patients with stable grades II and III glioma. *Neuro-oncology practice*. 2015;2(1):20-31.
11. Bedetti C, Romoli M, Maschio M, Di Bonaventura C, Cesarini EN, Eusebi P, et al. Neuropsychiatric adverse events of antiepileptic drugs in brain tumour-related epilepsy: an Italian multicentre prospective observational study. *Eur J Neurol*. 2017;24(10):1283-9.
12. Klein M, Heimans JJ, Aaronson NK, van der Ploeg HM, Grit J, Muller M, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. *Lancet*. 2002;360(9343):1361-8.
13. Klein M, Taphoorn MJ, Heimans JJ, van der Ploeg HM, Vandertop WP, Smit EF, et al. Neurobehavioral status and health-related quality of life in newly diagnosed high-grade glioma patients. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2001;19(20):4037-47.
14. Rooney AG, McNamara S, Mackinnon M, Fraser M, Rampling R, Carson A, et al. Frequency, clinical associations, and longitudinal course of major depressive disorder in adults with cerebral glioma. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2011;29(32):4307-12.
15. Armstrong TS, Grant R, Gilbert MR, Lee JW, Norden AD. Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy. *Neuro-oncology*. 2016;18(6):779-89.
16. Reijs R, Aldenkamp AP, De Krom M. Mood effects of antiepileptic drugs. *Epilepsy & behavior : E&B*. 2004;5 Suppl 1:S66-76.
17. Berntsson SG, Merrell RT, Amirian ES, Armstrong GN, Lachance D, Smits A, et al. Glioma-related seizures in relation to histopathological subtypes: a report from the glioma international case-control study. *Journal of Neurology*. 2018;265(6):1432-42.
18. Maschio M, Beghi E, Casazza MML, Colicchio G, Costa C, Banfi P, et al. Patterns of care of brain tumor-related epilepsy. A cohort study done in Italian Epilepsy Center. *PLoS One*. 2017;12(7):e0180470.
19. Perucca E. Optimizing antiepileptic drug treatment in tumoral epilepsy. 2013;54(s9):97-104.
20. Chung S, Wang N, Hank N. Comparative retention rates and long-term tolerability of new antiepileptic drugs. *Seizure*. 2007;16(4):296-304.
21. Knudsen-Baas KM, Johannesen TB, Myklebust TÅ, Aarseth JH, Owe JF, Gilhus NE, et al. Antiepileptic and psychiatric medication in a nationwide cohort of patients with glioma WHO grade II-IV. *Journal of Neuro-Oncology*. 2018;140(3):739-48.
22. Belcastro V, Pisani LR, Bellocchi S, Casiraghi P, Gorgone G, Mula M, et al. Brain tumor location influences the onset of acute psychiatric adverse events of levetiracetam therapy: an observational study. *J Neurol*. 2017;264(5):921-7.
23. Vecht CJ, Kerkhof M, Duran-Pena A. Seizure prognosis in brain tumors: new insights and evidence-based management. *The oncologist*. 2014;19(7):751-9.

24. Chen B, Choi H, Hirsch LJ, Katz A, Legge A, Buchsbaum R, et al. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. *Epilepsy & Behavior*. 2017;76:24-31.
25. Brunbech L, Sabers A. Effect of Antiepileptic Drugs on Cognitive Function in Individuals with Epilepsy. *Drugs*. 2002;62(4):593-604.
26. Klein M, Engelberts NH, van der Ploeg HM, Kasteleijn-Nolst Trenite DG, Aaronson NK, Taphoorn MJ, et al. Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. *Annals of neurology*. 2003;54(4):514-20.
27. Helmstaedter C, Witt JA. The effects of levetiracetam on cognition: a non-interventional surveillance study. *Epilepsy & behavior : E&B*. 2008;13(4):642-9.
28. de Groot M, Douw L, Sizoo EM, Bosma I, Froklage FE, Heimans JJ, et al. Levetiracetam improves verbal memory in high-grade glioma patients. *Neuro-oncology*. 2013;15(2):216-23.
29. Glantz MJ, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. 2000;54(10):1886-93.
30. Rooney AG, Brown PD, Reijneveld JC, Grant R. Depression in glioma: a primer for clinicians and researchers. *J Neurol Neurosurg Psychiatry*. 2014;85(2):230-5.
31. Taphoorn MJB, Klein M. Cognitive deficits in adult patients with brain tumours. *The Lancet Neurology*. 2004;3(3):159-68.
32. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta neuropathologica*. 2016;131(6):803-20.
33. Deckers CLP, Hekster YA, Keyser A, Meinardi H, Renier WO. Drug load in clinical trials: A neglected factor. *Clinical Pharmacology & Therapeutics*. 1997;62(6):592-5.
34. Nederland Z. Farmacotherapeutisch Kompas [Available from: <https://farmacotherapeutischkompas.nl>].
35. Scott-Lennox J, Bryant-Comstock L, Lennox R, Baker GA. Reliability, validity and responsiveness of a revised scoring system for the Liverpool Seizure Severity Scale. *Epilepsy research*. 2001;44(1):53-63.
36. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta psychiatrica Scandinavica*. 1983;67(6):361-70.
37. Hays RD, Sherbourne CD, Mazel R. User's Manual for the Medical Outcomes Study (MOS) Core Measures of Health-Related Quality of Life. Santa Monica, CA: RAND Corporation; 1995.
38. Douw L, Klein M, Fagel SSAA, van den Heuvel J, Taphoorn MJB, Aaronson NK, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. *The Lancet Neurology*. 2009;8(9):810-8.
39. Spinhoven P, Ormel J, Sloekers PP, Kempen GI, Speckens AE, Van Hemert AM. A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. *Psychological medicine*. 1997;27(2):363-70.
40. Shrier I, Platt RW. Reducing bias through directed acyclic graphs. *BMC Medical Research Methodology*. 2008;8(1):70.
41. Vittinghoff E, McCulloch CE. Relaxing the Rule of Ten Events per Variable in Logistic and Cox Regression. *American Journal of Epidemiology*. 2007;165(6):710-8.
42. Breitbart W, Bruera E, Chochinov H, Lynch M. Neuropsychiatric syndromes and psychological symptoms in patients with advanced cancer. *Journal of Pain and Symptom Management*. 1995;10(2):131-41.
43. Josephson CB, Engbers JD, Jette N, Patten SB, Singh S, Sajobi TT, et al. Prediction Tools for Psychiatric Adverse Effects After Levetiracetam Prescription. *JAMA neurology*. 2019;76(4):440-6.

## Supplementary material

**Supplementary Table 1.** List with defined daily dosages, as defined by the World Health Organisation, of antiepileptic drugs prescribed in this study.

Antiepileptic drug	Defined daily dosage	Unit
Carbamazepine	1	g
Clonazepam	8	mg
Clobazam	20	mg
Gabapentin	1.8	g
Lacosamide	0.3	g
Lamotrigine	0.3	g
Levetiracetam	1.5	g
Phenytoin	0.3	g
Pregabalin	0.3	g
Topiramate	0.3	g
Valproic acid	1.5	g
Zonisamide	0.2	g

G=gram, mg=milligram

**Supplementary Table 2.** Medications prescribed to glioma patients in our study with corresponding depressive, anxiety and cognitive adverse effects.

Medication	No. of patients (n=272)	Adverse effects		
		Depressive <sup>a</sup>	Anxiety <sup>b</sup>	Cognitive <sup>c</sup>
Acenocoumarol	7	-	-	-
Acetylsalicyl acid	1	-	Reported	Reported
Alendronic acid	4	-	-	-
Alendronic acid/colecalciferol	2	-	-	-
Alfacalcidol	2	-	-	0,1-1%
Alfuzosin	1	-	-	-
Aliskiren	1	-	-	-
Allopurinol	1	<0,01%	-	-
Amantadine	1	>1%	>1%	>1%
Amitryptiline*	3	0,01-0,1%	0,1-1%	>1%
Amlodipine	11	0,1-1%	-	0,01-0,1%
Apixaban	1	-	-	-
Aripiprazole	1	0,1-1%	>1%	-
Atorvastatin	6	Reported	-	-
Azelastine/fluticasone	1	-	-	-
Barnidipine	2	-	-	-

Supplementary Table 2. Continued

Medication	No. of patients (n=272)	Adverse effects		
		Depressive <sup>a</sup>	Anxiety <sup>b</sup>	Cognitive <sup>c</sup>
Beclomethasone	2	Reported	Reported	-
Beclomethasone/formoterol	2	Reported	0,1-1%	-
Biperiden	1	-	0,01-0,1%	0,01-0,1%
Bisoprolol	1	0,1-1%	-	-
Budesonide	1	0,1-1%	0,1-1%	-
Cabergoline	1	>1%	-	-
Calcipotriol/betamethasone	1	-	-	-
Calcium carbonate	2	-	-	-
Calcium carbonate/colecalciferol	8	-	-	-
Carbamazepine <sup>*/d</sup>	13	0,1-1%	-	<0,01%
Carbasalate calcium	9	-	-	-
Carbomer	1	-	-	-
Celecoxib	4	0,1-1%	0,1-1%	0,01-0,1%
Cetirizine	1	0,01-0,1%	-	0,01-0,1%
Cholecalciferol or colecalciferol	9	-	-	-
Ciclesonide	1	Reported	Reported	-
Citalopram <sup>*/**</sup>	1	-	>1%	>1%
Clemastine	1	-	-	-
Clobazam <sup>**</sup>	5	>1%	0,1-1%	>1%
Clonazepam	6	>1%	>1%	>1%
Clopidogrel	9	-	-	<0,01%
Codeine	1	Reported	Reported	reported
Co-trimoxazol	7	Reported	-	-
Cromoglicic acid	1	-	-	-
Dabigatran	1	-	-	-
Dalteparin	1	-	-	-
Desloratidine	2	-	-	-
Dexamethasone	33	>1%	>1%	-
Dextran/hypromellose	1	-	-	-
Diazepam <sup>**</sup>	2	>1% <sup>f</sup>	-	>1%
Diclofenac	4	<0,01%	<0,01%	<0,01%
Diltiazem	2	-	0,1-1%	-
Doxazosin	1	0,1-1%	0,1-1%	-
Dutasteride	1	Reported	-	-
Enalapril	4	>1%	0,1-1%	0,1-1%
Esomeprazole	4	0,01-0,1%	-	0,01-0,1%
Estradiol	1	>1%	0,1-1%	-
Estradiol/dydrogesterone	2	>1%	>1% <sup>g</sup>	-
Etanercept	1	Reported	-	-
Ethinylestradiol/levonorgestrel	2	>1%	>1% <sup>g</sup>	-
Etoricoxib	4	0,1-1%	0,1-1%	0,1-1%
Ezetimibe	2	-	-	-
Ezetimibe/simvastatin	1	Reported	-	Reported

Supplementary Table 2. Continued

Medication	No. of patients (n=272)	Adverse effects		
		Depressive <sup>a</sup>	Anxiety <sup>b</sup>	Cognitive <sup>c</sup>
Ezetimibe/atorvastatin	1	0,1-1%	-	Reported
Finasteride	2	0,1-1%	-	-
Flecainide	1	0,01-0,1%	0,1-1%	0,1-1%
Fluorouracil	1	-	-	-
Fluoxetine <sup>*/**</sup>	1	0,1-1%	>1%	>1%
Fluticasone	4	<0,01%	<0,01%	-
Folic acid	2	<0,01%	-	-
Formoterol	1	-	0,1-1%	-
Fosinopril	1	>1% <sup>f</sup>	-	Reported
Furosemide	1	-	-	-
Fusidic acid	1	-	-	-
Gabapentin	4	>1%	>1%	>1%
Gemfibrozil	1	0,01-0,1%	-	-
Gliclazide	2	-	-	-
Glycopyrronium bromide	1	>1% <sup>f</sup>	Reported	>1%
Granisetron	5	-	-	-
Hydrochlorothiazide	11	0,01-0,1%	-	-
Hydroxychloroquine	1	-	0,01-0,1%	-
Hypromellose	1	-	-	-
Indapamide	1	-	-	-
Insulin aspart	2	-	-	-
Insulin glargine	1	-	-	-
Ipratropium bromide	1	-	-	-
Irbesartan	3	-	-	-
Isosorbide dinitrate	2	-	-	-
Itraconazole	1	-	-	>1%
Ketoconazole	1	-	-	-
Lacosamide	15	>1%	0,1-1%	>1%
Lactulose	5	-	-	-
Lamotrigine <sup>*</sup>	12	-	-	<0,01%
Letrozole	1	>1%	0,1-1%	0,1-1%
Levetiracetam	122	>1%	>1%	0,1-1%
Levocetirizine	1	Reported	Reported	-
Levodopa/carbidopa	3	>1%	-	>1%
Levonorgestrel	1	>1%	>1% <sup>g</sup>	-
Levothyroxine	7	-	-	-
Lidocaine	1	-	-	-
Lisinopril	4	0,1-1%	-	0,01-0,1%
Loratidine	1	-	>1% <sup>g</sup>	-
Lorazepam <sup>**</sup>	1	0,1-1%	-	0,1-1%
Losartan	5	Reported	-	-
Losartan/hydrochlorothiazide	1	0,1-1%	0,1-1%	-
Macrogol	19	-	-	-

Supplementary Table 2. Continued

Medication	No. of patients (n=272)	Adverse effects		
		Depressive <sup>a</sup>	Anxiety <sup>b</sup>	Cognitive <sup>c</sup>
Magnesium hydroxide	1	-	-	-
Melatonin	1	0,01-0,1%	0,1-1%	0,01-01%
Mesalazine	1	Reported	-	-
Metformin	10	-	-	-
Methotrexate	2	0,1-1%	-	-
Methylphenidate	4	>1%	>1%	-
Metoclopramide	8	>1%	-	0,01-0,1%
Metoprolol	11	0,1-1%	0,01-0,1%	0,1-1%
Metronidazole	1	-	-	-
Miconazole	1	-	-	-
Midazolam	2	>1% <sup>f</sup>	-	>1%
Minocycline	1	-	-	Reported
Mirtazapine*	2	Reported	>1%	>1%
Mometasone furoate	2	-	-	-
Montelukast	2	0,1-1%	0,1-1%	0,01-0,1%
Nadroparin calcium	4	-	-	-
Naproxen	1	0,01-0,1%	-	0,01-0,1%
Nifedipine	1	<0,01%	0,1-1%	-
Nitrofurantoin	1	Reported	-	-
Norethisterone	1	<0,01%	-	-
Octreotide	1	-	-	-
Olanzapine	2	>1% <sup>f</sup>	-	-
Omeprazole	21	0,01-0,1%	0,01-0,1%	-
Ondansetron	1	-	-	-
Oxazepam**	6	>1% <sup>f</sup>	-	>1%
Oxycodone	3	>1%	>1%	>1%
Pantoprazole	28	0,01-0,1%	-	<0,01%
Paracetamol <sup>e</sup>	-	0,1-1%	-	0,1-1%
Paroxetine <sup>*/**</sup>	2	Reported	>1% <sup>g</sup>	>1%
Pegvisomant	1	-	0,1-1%	0,1-1%
Perindopril	7	0,1-1%	-	<0,01%
Phenytoin	3	-	>1% <sup>g</sup>	>1%
Polystyrene sulfonate	1	-	-	-
Pramipexole	2	Reported	Reported	>1%
Pravastatin	5	Reported	-	Reported
Prednisolone	4	>1%	>1%	-
Pregabalin**	4	0,1-1%	0,1-1%	>1%
Procarbazine	1	>1%	-	>1%
Propranolol**	3	0,01-0,1%	-	0,01-0,1%
Pyridoxine	1	-	-	-
Ranitidine	1	<0,01%	-	<0,01%
Ropinirole	1	Reported	>1% <sup>g</sup>	>1%
Salbutamol	5	-	-	-



Supplementary Table 2. Continued

Medication	No. of patients (n=272)	Adverse effects		
		Depressive <sup>a</sup>	Anxiety <sup>b</sup>	Cognitive <sup>c</sup>
Salmeterol/fluticasone	1	-	0,1-1%	-
Sertraline <sup>*/**</sup>	1	>1%	>1%	>1%
Sevelamer	1	-	-	-
Sildenafil	1	-	-	-
Simvastatin	12	Reported	-	<0,01%
Solifenacin	1	-	-	-
Sotalol	4	>1%	>1%	-
Spiroonolactone	1	-	-	0,1-1%
Sulfasalazine	1	0,1-1%	<0,01%	-
Tacrolimus	1	>1%	>1%	>1%
Tamsulosin	6	-	-	-
Temazepam	3	>1% <sup>f</sup>	-	>1%
Testosterone	2	>1% <sup>f</sup>	Reported	-
Ticagrelor	1	-	-	0,1-1%
Timolol/bimatoprost	1	0,1-1%	-	0,01-0,1%
Tiotropium bromide	1	-	-	-
Topiramate	10	>1%	>1%	>1%
Tramadol	6	0,01-0,1%	0,01-0,1%	0,01-0,1%
Trazodone*	1	Reported	>1% <sup>g</sup>	>1%
Triamcinolone	1	-	-	-
Ursodeoxycholic acid	1	-	-	-
Valproic acid*	53	Reported	-	>1%
Valsartan	3	-	-	-
Venlafaxine <sup>*/**</sup>	5	0,1-1%	-	>1%
Vildagliptin/metformin	1	-	-	-
Zonisamide	1	>1%	>1%	>1%

<sup>a</sup>The following adverse effects were considered depressive: depression, flat affect, lethargy, apathy, suicidal thoughts, mood disorder and mood swings; <sup>b</sup>The following adverse effects were considered anxiety: anxiety, nervousness, agitation and panic (attacks); <sup>c</sup>The following adverse effects were considered cognitive: cognitive impairment, concentration disorder, confusion, amnesia, attention disorder, reduced memory, bradyphrenia, aphasia, reduced alertness and disorientation; <sup>d</sup>Carbamazepine was considered as a medication with >1% risk of cognitive adverse effects, despite the percentages on Farmacotherapeutisch Kompas, based on literature;<sup>1,2</sup> <sup>e</sup>We did not include paracetamol in our analyses, as we were not confident this was reported adequately in the medical record; <sup>f</sup>Closely related adverse effect of depression and considered depressive, only indicated if >1%; <sup>g</sup>Closely related adverse effect of anxiety and considered as an anxiety adverse effect, only indicated if >1%;

\*These medications have a mood stabilizing indication according to Farmacotherapeutisch Kompas; \*\*These medications have an anxiolytic indication according to Farmacotherapeutisch Kompas,

**Supplementary Table 3.** Detailed information on the used questionnaires.

Questionnaire	Explanation
Study specific questionnaire	The following potential confounders were assessed in the study specific questionnaire: ethnicity, level of education, marital status, current employment status, availability of social support, prior depressive or anxiety disorder, and family history of mood disorders
Liverpool Seizure Severity Scale (LSSS)	Seizure severity was measured with a modified version of the Liverpool Seizure Severity Scale (LSSS), evaluating the seizure severity during the past four weeks. The questionnaire contains 12 items about seizure severity. The total severity score, after a linear transformation of the sum of responses, is expressed in a score ranging from 0 (no seizures) to 100 (most severe possible). <sup>3</sup>
Hospital Anxiety and Depression Scale (HADS)	This 14-item self-assessment scale consists of seven items related to depression and seven items related to anxiety. A cut-off of $\geq 8$ points (range 0-21) on the depression or anxiety domain was used to classify patients dichotomously as depressed or anxious, as this is seen as the preferred cut-off for detecting clinical depression and anxiety in the setting of an outpatient clinic. <sup>4,5</sup> Missing items were imputed by the subject's mean if at least half of items were answered. <sup>6</sup>
Medical Outcomes Study-Cognitive Functioning Scale (MOS-CFS)	The CFS includes six questions of less severe, day-to-day problems including reasoning, concentration and thinking, memory, attention and psychomotor function. The raw scores of this self-reported CFS were converted linearly to a 0-100 scale, with higher scores indicating less cognitive complaints. <sup>7</sup> Subsequently, these individual scores were converted into z-scores, based on the normative scores from the MOS study and matched on age. Subjective cognitive impairment was defined as 2 standard deviations (SD) below the mean of the reference population. Similar to previous studies in glioma patients, subjective cognitive impairment was defined as a categorical variable: 2 standard deviations (SD) below the mean of the reference population. <sup>1,8</sup>

**Supplementary Table 4.** Univariable analyses of predictor variables of depression.

Parameter		Depression ( $\geq 8$ points on the HADS-D)			
		No./total (%)	uOR	95% CI	p-value
Current AED use, dichotomised	No AEDs (ref.)	9/88 (10%)			
	$\geq 1$	38/184 (21%)	2.29	1.05-4.97	0.037*
Current AED use, specified	Monotherapy LEV	19/85 (22%)			
	Monotherapy VPA	6/32 (19%)	0.80	0.29-2.23	0.672
	Other	13/67 (19%)	0.84	0.38-1.85	0.658
	No AEDs	9/88 (10%)	0.40	0.17-0.93	0.034*
Medications $>1\%$ risk of DAEs, excluding AEDs	No (ref.)	27/195 (14%)			
	Yes	20/77 (26%)	2.18	1.14-4.19	0.019*
Mood stabilizing medication <sup>a</sup>	No (ref.)	35/197 (18%)			
	Yes	12/75 (16%)	0.88	0.43-1.81	0.731
Total AED load		47/271 (17%)	1.26	0.89-1.79	0.195
Seizure severity <sup>b</sup>		47/272 (17%)	1.03	1.00-1.07	0.055*
Status epilepticus <sup>c</sup>	No (ref.)	35/176 (20%)			
	Yes	6/33 (18%)	0.90	0.34-2.34	0.821
Age		47/272 (17%)	1.00	0.97-1.03	0.948
Sex	Female (ref.)	18/113 (16%)			
	Male	29/159 (18%)	1.18	0.62-2.24	0.620
Time since diagnosis		47/272 (17%)	1.00	0.99-1.00	0.360
Ethnicity	Caucasian (ref.)	42/252 (17%)			
	Other	3/12 (25%)	1.67	0.43-6.42	0.458
Level of education	Low (ref.)	6/72 (8%)			
	Medium/ high	41/200 (21%)	2.84	1.15-7.00	0.024*
Marital status	Partner (ref.)	38/222 (17%)			
	No partner	9/50 (18%)	1.06	0.48-2.37	0.881
Employment status	Not incapacitated to work (ref.)	28/199 (14%)			
	Incapacitated to work	19/73 (26%)	2.15	1.11-4.15	0.023*
Social support	Adequate (ref.)	44/263 (17%)			
	Not adequate	3/9 (33%)	2.49	0.60-10.33	0.209
History of mood disorder treatment <sup>d</sup>	No (ref.)	39/241 (16%)			
	Yes	8/31 (26%)	1.80	0.75-4.32	0.187
Mood disorder in family <sup>e</sup>	No (ref.)	35/193 (18%)			
	Yes	12/79 (15%)	0.81	0.40-1.65	0.560
Most recent tumour grade <sup>f</sup>	Low (grade II, ref.)	30/135 (22%)			
	High (grade III & IV)	17/137 (12%)	0.50	0.26-0.95	0.034*

Supplementary Table 4. Continued

Parameter		Depression ( $\geq 8$ points on the HADS-D)			
		No./total (%)	uOR	95% CI	p-value
Extent of last resection	Biopsy (ref.)	3/37 (8%)			
	Resection	43/228 (19%)	2.63	0.77-8.98	0.122
Radiotherapy	No (ref.)	12/55 (22%)			
	Yes	35/217 (16%)	0.69	0.33-1.44	0.321
Chemo- and or immunotherapy	No (ref.)	14/79 (18%)			
	Yes	33/193 (17%)	0.96	0.48-1.91	0.902
Tumour lobe	Non-frontal (ref.)	17/110 (15%)			
	Frontal	30/162 (19%)	1.24	0.65-2.39	0.512
KPS	$\geq 70$ (ref.)	43/266 (16%)			
	$< 70$	4/6 (67%)	10.37	1.84-58.42	0.008*

<sup>a</sup>Excluding mood stabilizing medication for treatment of depression first prescribed after glioma diagnosis; <sup>b</sup>Score 0-100 measured with the Liverpool Seizure Severity Scale; <sup>c</sup>Status epilepticus was defined as ongoing seizures for  $\geq 30$  minutes if convulsive or  $\geq 60$  minutes if non-convulsive, because it has been thought long-term consequences might occur after this timeframe; <sup>d</sup>Prior to glioma diagnosis, treatment started after glioma diagnosis was considered potentially in the causal pathway, as most medications with depressive and anxiety adverse effects were started after glioma diagnosis, and therefore not further analysed; <sup>e</sup>First and/ or second degree relatives; <sup>f</sup>Diffuse astrocytoma isocitrate dehydrogenase (IDH)-wildtype was considered high-grade; \* $p < 0.1$ ; AEDs=Antiepileptic drugs; CI=Confidence Interval; DAEs=Depressive Adverse Effects; HADS-D=Hospital Anxiety and Depression Scale-Depression subscale; KPS=Karnofsky Performance Status; LEV=Levetiracetam; ref.=reference category; uOR=unadjusted Odds Ratio; VPA=Valproic acid

Supplementary Table 5. Univariable analyses of predictor variables of anxiety

Parameter		Anxiety ( $\geq 8$ points on the HADS-A)			
		No. (%)	uOR	95% CI	p-value
Current AED use, dichotomised	No AEDs (ref.)	17/88 (19%)			
	$\geq 1$	47/184 (26%)	1.43	0.77-2.68	0.259
Current AED use, specified	Monotherapy LEV (ref.)	27/85 (32%)			
	Monotherapy VPA	5/32 (16%)	0.40	0.14-1.15	0.088*
	Other	15/67 (22%)	0.62	0.30-1.29	0.201
	No AEDs	17/88 (19%)	0.51	0.26-1.04	0.062*
Medications $> 1\%$ risk of AAEs, excluding AEDs	No (ref.)	48/213 (23%)			
	Yes	16/59 (27%)	1.28	0.66-2.47	0.463
Anxiolytic medication <sup>a</sup>	No (ref.)	57/249 (23%)			
	Yes	7/23 (30%)	1.47	0.58-3.76	0.417
Total AED load		64/271 (24%)	1.04	0.75-1.45	0.818
Seizure severity <sup>b</sup>		64/272 (24%)	1.03	1.00-1.07	0.044*
Status epilepticus <sup>c</sup>	No (ref.)	46/176 (26%)			
	Yes	6/33 (18%)	0.63	0.24-1.62	0.335
Age		64/272 (24%)	0.98	0.96-1.00	0.075*

Supplementary Table 5. Continued

Parameter		Anxiety ( $\geq 8$ points on the HADS-A)			
		No. (%)	uOR	95% CI	p-value
Sex	Female (ref.)	32/113 (28%)			
	Male	32/159 (20%)	0.64	0.36-1.12	0.118
Time since diagnosis		64/272 (24%)	1.00	0.99-1.00	0.240
Ethnicity	Caucasian (ref.)	56/252 (22%)			
	Other	6/12 (50%)	3.50	1.09-11.28	0.036*
Level of education	Low (ref.)	14/72 (19%)			
	Medium/ high	50/200 (25%)	1.38	0.71-2.69	0.342
Marital status	Partner (ref.)	52/222 (23%)			
	No partner	12/50 (24%)	1.03	0.50-2.12	0.931
Employment status	Not incapacitated to work (ref.)	43/199 (22%)			
	Incapacitated to work	21/73 (29%)	1.47	0.80-2.69	0.219
Social support	Adequate (ref.)	59/263 (22%)			
	Not adequate	5/9 (56%)	4.32	1.13-16.61	0.033*
History of mood disorder treatment <sup>d</sup>	No (ref.)	50/241 (21%)			
	Yes	14/31 (45%)	3.15	1.45-6.81	0.004*
Mood disorder in family <sup>e</sup>	No (ref.)	41/193 (21%)			
	Yes	23/79 (29%)	1.52	0.84-2.76	0.166
Most recent tumour grade <sup>f</sup>	Low (grade II, ref.)	34/135 (25%)			
	High (grade III & IV)	30/137 (22%)	0.83	0.48-1.46	0.523
Extent of last resection	Biopsy (ref.)	9/37 (24%)			
	Resection	53/228 (23%)	0.94	0.42-2.12	0.886
Radiotherapy	No (ref.)	13/55 (24%)			
	Yes	51/217 (24%)	0.99	0.50-2.00	0.983
Chemo- and or immunotherapy	No (ref.)	22/79 (28%)			
	Yes	42/193 (22%)	0.72	0.40-1.31	0.284
Tumour lobe	Non-frontal (ref.)	24/110 (22%)			
	Frontal	40/162 (25%)	1.18	0.66-2.09	0.584
KPS	$\geq 70$ (ref.)	62/266 (23%)			
	$< 70$	2/6 (33%)	1.65	0.29-9.20	0.571

<sup>a</sup>Excluding anxiolytic medication for treatment of anxiety first prescribed after glioma diagnosis; <sup>b</sup>Score 0-100 measured with the Liverpool Seizure Severity Scale; <sup>c</sup>Status epilepticus was defined as ongoing seizures for  $\geq 30$  minutes if convulsive or  $\geq 60$  minutes if non-convulsive, because it has been thought long-term consequences might occur after this timeframe; <sup>d</sup>Prior to glioma diagnosis, treatment started after glioma diagnosis was considered potentially in the causal pathway, as most medications with depressive and anxiety adverse effects were started after glioma diagnosis, and therefore not further analysed; <sup>e</sup>First and/ or second degree relatives; <sup>f</sup>Diffuse astrocytoma isocitrate dehydrogenase (IDH)-wildtype was considered high-grade; \* $p < 0.1$ ; AAEs=Anxiety Adverse Effects; AEDs=Antiepileptic Drugs; CI=Confidence Interval; HADS-A=Hospital Anxiety and Depression Scale-Anxiety subscale; KPS=Karnofsky Performance Status; LEV=levetiracetam; ref.=reference category; uOR=unadjusted Odds Ratio; VPA=valproic acid

**Supplementary Table 6.** Univariable analyses of possible confounding predictor variables of subjective cognitive impairment.

Parameter		Cognitive impairment ( $\geq 2SD$ below the mean of normative data from the MOS)			
		No. (%)	uOR	95% CI	p-value
Current AED use, dichotomised	No AEDs	14/88 (16%)			
	$\geq 1$	38/184 (21%)	1.38	0.70-2.70	0.353
Current AED use, specified	Monotherapy VPA (ref.)	9/32 (28%)			
	Monotherapy LEV	12/85 (14%)	0.42	0.16-1.12	0.084*
	Other	17/67 (25%)	0.87	0.34-2.24	0.771
Medications >1% risk of CAEs, excluding AEDs	No AEDs	14/88 (16%)	0.48	0.19-1.26	0.138
	No (ref.)	40/235 (17%)			
	Yes	12/37 (32%)	2.34	1.09-5.04	0.030*
Total AED load		51/271 (19%)	1.36	0.98-1.91	0.070*
Seizure severity <sup>a</sup>		52/272 (19%)	1.04	1.01-1.08	0.012*
Status epilepticus <sup>b</sup>	No (ref.)	34/176 (19%)			
	Yes	7/33 (21%)	1.12	0.45-2.81	0.802
Age		52/272 (19%)	1.02	0.99-1.05	0.153
Sex	Female (ref.)	27/113 (24%)			
	Male	25/159 (16%)	0.59	0.32-1.09	0.093*
Time since diagnosis		52/272 (19%)	1.00	1.00-1.00	0.915
Ethnicity <sup>c</sup>	Caucasian (ref.)	51/252 (20%)			
	Other	1/13 (8%)	0.33	0.04-2.59	0.290
Level of education	Low (ref.)	15/72 (21%)			
	Medium/ high	37/200 (19%)	0.86	0.44-1.69	0.666
Marital status	Partner (ref.)	44/222 (20%)			
	No partner	8/50 (16%)	0.77	0.34-1.76	0.536
Employment status <sup>d</sup>	Not incapacitated to work (ref.)	30/199 (15%)			
	Incapacitated to work	22/73 (30%)	2.43	1.29-4.58	0.006*
Social support	Adequate (ref.)	4/9 (44%)			
	Not adequate	48/263 (18%)	3.58	0.93-13.84	0.064*
History of mood disorder treatment <sup>e</sup>	No (ref.)	44/241 (18%)			
	Yes	8/31 (26%)	1.56	0.65-3.71	0.317
Mood disorder in family <sup>f</sup>	No (ref.)	31/193 (16%)			
	Yes	21/79 (27%)	1.89	1.01-3.55	0.047*
Most recent tumour grade <sup>g</sup>	Low (grade II, ref.)	24/135 (18%)			
	High (grade III & IV)	28/137 (20%)	1.19	0.65-2.18	0.577
Extent of last resection	Biopsy (ref.)	5/37 (14%)			
	Resection	47/228 (21%)	1.66	0.61-4.50	0.317

Supplementary Table 6. Continued

Parameter		Cognitive impairment ( $\geq 2SD$ below the mean of normative data from the MOS)			
		No. (%)	uOR	95% CI	p-value
Radiotherapy	No (ref.)	8/55 (15%)			
	Yes	44/217 (20%)	1.49	0.66-3.39	0.337
Chemo- and or immunotherapy	No (ref.)	16/79 (20%)			
	Yes	36/193 (19%)	0.90	0.47-1.74	0.761
Tumour lobe	Non-frontal (ref.)	22/110 (20%)			
	Frontal	30/162 (19%)	0.91	0.49-1.68	0.909
KPS <sup>b</sup>	$\geq 70$ (ref.)	48/266 (18%)			
	<70	4/6 (67%)	9.08	1.62-51.03	0.012*

<sup>a</sup>Score 0-100 measured with the Liverpool Seizure Severity Scale; <sup>b</sup>Status epilepticus was defined as ongoing seizures for  $\geq 30$  minutes if convulsive or  $\geq 60$  minutes if non-convulsive, because it has been thought long-term consequences might occur after this timeframe; <sup>c</sup>Regarding ethnicity we imputed a non-Caucasian for a missing variable to handle the problem of 0 in a cell; <sup>d</sup>Employment status was not considered a confounding predictor variable, as being incapacitated to work is likely a cause of cognitive impairment; <sup>e</sup>Prior to glioma diagnosis, treatment started after glioma diagnosis was considered potentially in the causal pathway, as most medications with depressive and anxiety adverse effects were started after glioma diagnosis, and therefore not further analysed; <sup>f</sup>First and/ or second degree relatives; <sup>g</sup>Diffuse astrocytoma isocitrate dehydrogenase (IDH)-wildtype was considered high-grade; <sup>h</sup>KPS was not considered a confounding predictor variable, as a low KPS is likely a cause of cognitive impairment; \* $p < 0.1$ ; AEDs=Antiepileptic Drugs; CAEs=Cognitive Adverse Effects; CI=Confidence Interval; KPS=Karnofsky Performance Status; LEV=levetiracetam; MOS=Medical Outcomes Study; ref.=reference category; uOR=unadjusted Odds Ratio; VPA=Valproic acid

**Supplementary Table 7.** Unadjusted and adjusted odds ratios of the predictor variables of depression with current AED use specified in the multivariable analysis

Parameter		Depression ( $\geq 8$ points on the HADS-D)					
		uOR	95% CI	p-value	aOR	95% CI	p-value
Current AED use, specified	Monotherapy LEV (ref.)						
	Monotherapy VPA	0.80	0.29-2.23	0.672	0.76	0.26-2.23	0.616
	Other	0.84	0.38-1.85	0.658	0.61	0.25-1.47	0.270
	No AEDs	0.40	0.17-0.93	0.065	0.42	0.17-1.06	0.065
Medications >1% risk of DAEs <sup>a</sup>	None (ref.)						
	$\geq 1$	2.18	1.14-4.19	0.019*	2.31	1.13-4.71	0.021*
Seizure severity		1.03	1.00-1.07	0.055	1.02	0.99-1.06	0.208
Level of education	Low (ref.)						
	Medium/ high	2.84	1.15-7.00	0.024*	2.18	0.85-5.61	0.105
Employment status	Not incapacitated to work (ref.)						
	Incap. to work	2.15	1.11-4.15	0.023*	2.20	1.07-4.55	0.033*
Most recent tumour grade <sup>2</sup>	Low (grade II, ref.)						
	High (grade III & IV)	0.50	0.26-0.95	0.034*	0.50	0.24-1.01	0.053
KPS	$\geq 70$ (ref.)						
	<70	10.37	1.84-58.42	0.008*	9.42	1.55-57.15	0.015*

<sup>a</sup>Excluding AEDs; <sup>2</sup>Diffuse astrocytoma isocitrate dehydrogenase (IDH)-wildtype was considered high-grade; \* $p < 0.05$ ; AED=Antiepileptic Drug; aOR=adjusted Odds Ratio; CI=Confidence Interval; DAEs=Depressive Adverse Effects; HADS-D=Hospital Anxiety and Depression Scale-Depression subscale; KPS=Karnofsky Performance Status; LEV=Levetiracetam; ref.=reference category; uOR=unadjusted Odds Ratio; VPA=Valproic acid



**Supplementary Table 8.** Unadjusted and adjusted odds ratios of the predictor variables of anxiety with current AED use specified in the multivariable analysis

Parameter		Anxiety ( $\geq 8$ points on the HADS-A)					
		uOR	95% CI	p-value	aOR	95% CI	p-value
Current AED use, specified	Monotherapy LEV (ref.)						
	Monotherapy VPA	0.40	0.14-1.15	0.088	0.55	0.19-1.65	0.289
	Other	0.62	0.30-1.29	0.201	0.57	0.26-1.24	0.154
	No AEDs	0.51	0.26-1.04	0.062	0.65	0.30-1.37	0.253
Seizure severity		1.03	1.00-1.07	0.044*	1.03	1.00-1.07	0.087
Age		0.98	0.96-1.00	0.075	0.98	0.96-1.01	0.186
Ethnicity	Caucasian (ref.)						
	Other	3.50	1.09-11.28	0.036*	2.85	0.82-9.89	0.098
Social support	Adequate (ref.)						
	Not adequate	4.32	1.13-16.61	0.033*	3.65	0.82-16.13	0.088
History of mood disorder treatment*	No (ref.)						
	Yes	3.15	1.45-6.81	0.004*	2.86	1.26-6.50	0.012*

\*Prior to glioma diagnosis; \* $p < 0.05$ ; AED=Antiepileptic Drug; aOR=adjusted odds ratio; CI=Confidence Interval; HADS-A=Hospital Anxiety and Depression Scale-Anxiety subscale; uOR=unadjusted Odds Ratio; LEV=Levetiracetam; ref.=reference category; VPA=Valproic acid

**Supplementary Table 9.** Unadjusted and adjusted odds ratios of the predictor variables of subjective cognitive impairment with current AED use specified in the multivariable analysis.

Parameter		Impaired subjective cognition ( $\geq 2SD$ below the mean of normative data from the MOS)					
		uOR	95% CI	p-value	aOR	95% CI	p-value
Current AED use, specified	Monotherapy VPA (ref.)						
	Monotherapy LEV	0.42	0.16-1.12	0.084	0.40	0.14-1.11	0.078
	Other AED use	0.87	0.34-2.24	0.771	0.48	0.15-1.51	0.209
	No AEDs	0.48	0.19-1.26	0.138	0.67	0.22-1.98	0.463
Medications >1% risk of CAEs <sup>a</sup>	None (ref.)						
	$\geq 1$	2.34	1.09-5.04	0.030*	2.11	0.93-4.78	0.075
Seizure severity		1.04	1.01-1.08	0.012*	1.04	1.00-1.08	0.030*
Total AED load		1.36	0.98-1.91	0.070	1.37	0.79-2.39	0.264
Sex	Female (ref.)						
	Male	0.59	0.32-1.09	0.093	0.62	0.32-1.18	0.143
Social support	Adequate (ref.)						
	Not adequate	3.58	0.93-13.84	0.064	2.80	0.60-13.06	0.190
Mood disorder in family <sup>b</sup>	No (ref.)						
	Yes	1.89	1.01-3.55	0.047*	1.48	0.74-2.93	0.265

<sup>a</sup>Excluding AEDs; <sup>b</sup>First and/ or second degree relatives; \* $p < 0.05$ ; AED=Antiepileptic Drug; aOR=adjusted Odds Ratio; CAEs=Cognitive Adverse Effects; CI=Confidence Interval; LEV=Levetiracetam; MOS=Medical Outcomes Study; ref.=reference category; uOR=unadjusted Odds Ratio; VPA=Valproic acid

## References

1. Klein M, Heimans JJ, Aaronson NK, van der Ploeg HM, Grit J, Muller M, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study *Lancet*. 2002 Nov;360:1361-1368. Article
2. Klein M, Engelberts NH, van der Ploeg HM, Kasteleijn-Nolst Trenite DG, Aaronson NK, Taphoorn MJ, et al. Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life *Annals of neurology*. 2003 Oct;54:514-520.
3. Scott-Lennox J, Bryant-Comstock L, Lennox R, Baker GA. Reliability, validity and responsiveness of a revised scoring system for the Liverpool Seizure Severity Scale Epilepsy research. 2001 Apr;44:53-63.
4. Zigmond AS, Snaith RP. The hospital anxiety and depression scale *Acta psychiatrica Scandinavica*. 1983 Jun;67:361-370.
5. Rooney AG, McNamara S, Mackinnon M, Fraser M, Rampling R, Carson A, et al. Screening for major depressive disorder in adults with cerebral glioma: an initial validation of 3 self-report instruments *Neuro-oncology*. 2013 Jan;15:122-129.
6. Bell ML, Fairclough DL, Fiero MH, Butow PN. Handling missing items in the Hospital Anxiety and Depression Scale (HADS): a simulation study *BMC Res Notes*. 2016 Oct 22;9:479.
7. Hays RD, Sherbourne CD, Mazel R. User's Manual for the Medical Outcomes Study (MOS) Core Measures of Health-Related Quality of Life. . Santa Monica, CA: RAND Corporation; 1995.
8. Bosma I, Reijneveld JC, Douw L, Vos MJ, Postma TJ, Aaronson NK, et al. Health-related quality of life of long-term high-grade glioma survivors *Neuro-oncology*. 2009 Feb;11:51-58.